Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
RationaleThere is an extensive literature showing that the CB1 cannabinoid receptor antagonist rimonabant (SR141716) decreases alcohol consumption in animals, but little is known about its effects in human alcohol drinkers.MethodsIn this study, 49 nontreatment-seeking heavy alcohol drinkers participated in a 3-week study. After a 1-week baseline, participants received either 20 mg/day of rimonabant or placebo for 2 weeks under double-blind conditions. During these 3 weeks, participants reported their daily alcohol consumption by telephone. Subsequently, they participated in an alcohol self-administration paradigm in which they received a priming dose of alcohol followed by the option of consuming either eight alcohol drinks or receiving $3.00 for each nonconsumed drink. Endocrine measures and self-rating scales were also obtained.ResultsRimonabant did not change alcohol consumption during the 2 weeks of daily call-ins. Similarly, the drug did not change either alcohol self-administration or endocrine measures during the laboratory session.ConclusionWe conclude that the daily administration of 20 mg of rimonabant for 2 weeks has no effect on alcohol consumption in nontreatment-seeking heavy alcohol drinkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 2×
“, hypothalamus, cingulate, amygdala nuclei, nucleus accumbens, septum, and cerebellum), as well as in the periphery (i.e., adipose tissue, liver, and gastrointestinal tract; Pacher et al. 2006).”
Self-citationSULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 1×
“Participants who had a history of withdrawal symptoms which resulted in a score of 8 or above on the Clinical Institute Withdrawal Assessment (Sullivan et al. 1989) instrument were also excluded.”
Phasic Dopamine Release Evoked by Abused Substances Requires Cannabinoid Receptor Activation
Cheer, J. F., Wassum, K. M., Sombers, L. A., Heien, M. L. A. V., Ariansen, J. L., Aragona, B. J., Phillips, P. E. M., & Wightman, R. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-06.2007 · Cited by 374 · cited 2×
“Rimonabant also inhibited transient dopamine surges in the nucleus accumbens of freely moving rats, elicited not only by ethanol but also by nicotine and cocaine (Cheer et al. 2007) suggesting an obligatory role for endocannabinoids in the activation of the dopaminergic reward pathway by addictive substances.”
Weerts, E. M., Kim, Y. K., Wand, G. S., Dannals, R. F., Lee, J. S., Frost, J. J., & McCaul, M. E. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301440 · Cited by 147
Cited by
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
Ceccarini, J., Hompes, T., Verhaeghen, A., Casteels, C., Peuskens, H., Bormans, G., Claes, S., & Van Laere, K. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0849-13.2014 · Cited by 111
Horder, J., Browning, M., Di Simplicio, M., Cowen, P. J., & Harmer, C. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111400649 · Cited by 48
“Other short-term studies of rimonabant have likewise reported no mood changes with rimonabant 40mg for 15 days (Huestis et al., 2007) or after rimonabant 20mg for 14 days (George et al., 2009).”
BackgroundKarlsson, R.-M., Adermark, L., Molander, A., Perreau-Lenz, S., Singley, E., Solomon, M., Holmes, A., Tanaka, K., Lovinger, D. M., Spanagel, R., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.027 · Cited by 44
“Thus, the CB1 receptor antagonist rimonabant was recently evaluated clinically as a candidate treatment for alcoholism (George et al., 2010; Soyka et al., 2008).”
BackgroundSelf-citationDistinct functions of endogenous cannabinoid system in alcohol abuse disorders
Basavarajappa, B. S., Joshi, V., Shivakumar, M., & Subbanna, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14780 · Cited by 37
“…human alcohol consumption and AUDs, although clinical studies on rimonabant have not been very successful and limited evidence suggests a non‐ significant reduction in relapse to heavy drinking in the rimonabant group compared with the placebo group (George et al., 2010; Soyka et al., 2008).”
Background
Metadata
- Authors
- George, D. T., Herion, D. W., Jones, C. L., Phillips, M. J., Hersh, J., Hill, D., Heilig, M., Ramchandani, V. A., Geyer, C., Spero, D. E., Singley, E. D., O’Malley, S. S., Bishai, R., Rawlings, R. R., & Kunos, G.
- Venue
- Psychopharmacology
- Published
- 2009-11-10
- Volume
- 208
- Issue
- 1
- Pages
- 37-44
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2047530912
- Cited by
- 74
- References
- 5
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. https://app.cochat.ai/papers/10.1007/s00213-009-1704-3
- The paper
- George, D. T., Herion, D. W., Jones, C. L., Phillips, M. J., Hersh, J., Hill, D., Heilig, M., Ramchandani, V. A., Geyer, C., Spero, D. E., Singley, E. D., O’Malley, S. S., Bishai, R., Rawlings, R. R., & Kunos, G. (2010). Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology. https://doi.org/10.1007/s00213-009-1704-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.